Vanguard Portfolio Management
CORT icon

Vanguard Portfolio Management’s Corcept Therapeutics CORT Stock Holding History

Vanguard Portfolio Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$439M Buy
5,044,638
+224,070
+5% +$13.5M 0.02% 778
2026
Q1 		$194M Buy
+4,820,568
New +$180M 0.01% 1157

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Vanguard Portfolio Management's CORT Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Corcept Therapeutics (CORT) stake by 4.6% in Q2 2026, buying an estimated $13.5M and bringing the position to 5,044,638 shares worth $439M. The position accounts for 0.02% of the portfolio, ranked #778.

Vanguard Portfolio Management first reported a position in CORT in Q1 2026 and has held it in 2 quarters since. 415 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Vanguard Portfolio Management held 5,044,638 shares of Corcept Therapeutics worth $439M as of Q2 2026.
  • Vanguard Portfolio Management bought 224,070 Corcept Therapeutics shares in Q2 2026, an estimated $13.5M.
  • Corcept Therapeutics made up 0.02% of Vanguard Portfolio Management's portfolio in Q2 2026, its #778 holding.
  • Vanguard Portfolio Management first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 415 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.